2026-07-21T17:02:23Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/181172024-02-12T19:47:17Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16962col_20.500.12105_16964col_20.500.12105_16975col_20.500.12105_16984col_20.500.12105_16986
Repisalud
author
Yun, Sergi
author
Enjuanes, Cristina
author
Calero, Esther
author
Hidalgo, Encarnación
author
Cobo, Marta
author
Llàcer, Pau
author
García-Pinilla, José Manuel
author
González-Franco, Álvaro
author
Núñez, Julio
author
Morales-Rull, José Luis
author
Beltrán, Paola
author
Delso, Cristina
author
Freixa-Pamias, Román
author
Moliner, Pedro
author
Corbella, Xavier
author
Comín-Colet, Josep
author
HERMeS trial investigators group
2024-02-12T19:47:17Z
2024-02-12T19:47:17Z
2020-09-17
10.1002/ehf2.12962
2055-5822
ESC heart failure
http://hdl.handle.net/10668/16269
32940428
http://hdl.handle.net/20.500.12105/18117
The role of non-invasive telemedicine (TM) combining telemonitoring and teleintervention by videoconference (VC) in patients recently admitted due to heart failure (HF) ('vulnerable phase' HF patients) is not well established. The aim of the Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS) trial is to assess the impact on clinical outcomes of implementing a TM service based on mobile health (mHealth), which includes remote daily monitoring of biometric data and symptom reporting (telemonitoring) combined with VC structured, nurse-based follow-up (teleintervention). The results will be compared with those of the comprehensive HF usual care (UC) strategy based on face-to-face on-site visits at the vulnerable post-discharge phase. We designed a 24 week nationwide, multicentre, randomized, controlled, open-label, blinded endpoint adjudication trial to assess the effect on cardiovascular (CV) mortality and non-fatal HF events of a TM-based comprehensive management programme, based on mHealth, for patients with chronic HF. Approximately 508 patients with a recent hospital admission due to HF decompensation will be randomized (1:1) to either structured follow-up based on face-to-face appointments (UC group) or the delivery of health care using TM. The primary outcome will be a composite of death from CV causes or non-fatal HF events (first and recurrent) at the end of a 6 month follow-up period. Key secondary endpoints will include components of the primary event analysis, recurrent event analysis, and patient-reported outcomes. The HERMeS trial will assess the efficacy of a TM-based follow-up strategy for real-world 'vulnerable phase' HF patients combining telemonitoring and teleintervention.
eng
Chronic care model
Chronic heart failure
Outcomes research
Telemedicine
Transitional care
mHealth
Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS).
research article